Rocket Pharmaceuticals is trading 5.03% down at $3.31, extending its decline from $3.48 on September 10, 2026, with no clear new company-specific negative catalyst identified.
- The September 10 Cantor conference highlighted three patients treated under the modified Danon disease protocol, with favorable safety and tolerability.
- Available coverage does not explicitly identify that update as the cause of the September 11 decline.
- The broader market is rising, so the move does not appear to reflect overall risk-off sentiment.